|
BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries.
Bottom Line:
BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries.Results from this study will contribute to improved cardiovascular risk prediction across different European populations.The present publication describes the rationale and design of the BiomarCaRE project.
View Article:
PubMed Central - PubMed
Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.
ABSTRACT
Show MeSH
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project. Related in: MedlinePlus |
Related In:
Results -
Collection
getmorefigures.php?uid=PMC4197377&req=5
Fig1: BiomarCaRE collaborating countries and cohorts across Europe. Asterisk indicates cohort with imaging data available Mentions: The collaborative BiomarCaRE consortium, an FP7 funded project, integrates the efforts of 25 academic institutions and five small/medium-sized, research intensive enterprises (SMEs) with a focus on cardiovascular biomarker research across Europe (Fig. 1). BiomarCaRE brings together large-scale epidemiological and clinical data and biomaterial resources across Europe and diverse expertise in epidemiology, clinical research, data and sample management, clinical chemistry, molecular biology, and biostatistics. The consortium capitalizes on in depth knowledge of omics-based candidate markers and integrates modern technologies of multiple biomarker assessment. It comprises 21 well-established prospective European population-based cohort studies, most of which were previously harmonized in the MORGAM Project [9], four cohorts of diseased subjects (disease cohorts, secondary prevention) and four clinical trials, totalling over 300,000 participants with a follow-up of over three million person years and storage of selected biomaterial of all participants in one central BiomaCaRE laboratory (University Heart Center Hamburg). This large individual-based database provides a unique opportunity to investigate the performance of established and novel biomarkers for Cardiovascular Risk Assessment across Europe.Fig. 1 |
View Article: PubMed Central - PubMed
Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.
